Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (48) Procanbid (procainamide hydrochloride extended-release tablets), Warner-Lambert,
...annually in the United States. The condition is responsible for more than 80 percent of sudden cardiac deaths (SCD). In the United States, approximately 400,000 SCDs occur each year. Jobson Medical ...
View Page

2.  CenterWatch: New Medical Therapies in Disease Category (812), Myocardial Ischemia
...lasting eight beats or more (p<0.001). In addition, there were fewer episodes of sudden cardiac death observed in the Ranexa group, with 56 deaths than in the placebo group, with ...
View Page

3.  Study Posting (1570) Trial #156491, Heart Failure, Morristown, NJ
...of enrollment • Patient has received a pacemaker within 60 days of enrollment • History of aborted sudden cardiac death, if patient has not received an ICD and has potentially lethal ventricular arrhythmia, VT ...
View Page

4.  CenterWatch Clinical Research Profile (4295) Trial #1821, Peninsula Cardiology Associates, P.A., Salisbury, MD
...high cholesterol, hypertension, heart failure, coronary and peripheral revascularization, sinus node dysfunction, atrial fibrillation and sudden cardiac death. In the past 9 years Peninsula Cardiology has collaborated on over 50 different trials ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (50), Coronary Artery Disease
...lasting eight beats or more (p<0.001). In addition, there were fewer episodes of sudden cardiac death observed in the Ranexa group, with 56 deaths than in the placebo group, with ...
View Page

6.  CenterWatch: New Medical Therapies in Disease Category (85), Hypertension (High Blood Pressure)
...standard therapy. In addition, in subjects treated with Inspra there was a 21% reduction in sudden cardiac death and 15% fewer subjects hospitalized for heart failure. Inspra was generally well tolerated compared ...
View Page

7.  CenterWatch: New Medical Therapies in Disease Category (281), Heart Failure
...standard therapy. In addition, in subjects treated with Inspra there was a 21% reduction in sudden cardiac death and 15% fewer subjects hospitalized for heart failure. Inspra was generally well tolerated compared ...
View Page